Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Takeda launches Outpost Medicine, grants rights to urinary incontinence compound; development stops

Executive Summary

Together with Frazier Healthcare Partners, Takeda Pharmaceutical Co. Ltd. launched a new company, Outpost Medicine, and granted the start-up exclusive global rights to its stress urinary incontinence project TAK233 (which Outpost renamed OP233).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register